Shao‐Lai Zhou, Dan Yin, Zhi‐Qiang Hu, Chu‐Bin Luo, Zheng‐Jun Zhou, Hao‐Yang Xin, Xin‐Rong Yang, Ying‐Hong Shi, Zheng Wang, Xiao‐Wu Huang, Ya Cao, Jia Fan, Jian Zhou – 1 April 2019 – Tumor‐associated neutrophils (TANs) play a crucial role in tumor development and progression in the cancer microenvironment. Despite increased understanding of TAN contributions to hepatocellular carcinoma (HCC) progression and prognosis, the direct interaction between TANs and HCC cells is not fully understood.

George N. Ioannou, Charles S. Landis, Ga‐Young Jin, W. Geoffrey Haigh, Geoffrey C. Farrell, Rahul Kuver, Sum P. Lee, Christopher Savard – 1 April 2019 – It is unclear what drives the development of fibrosing nonalcoholic steatohepatitis (NASH). We aimed to determine whether cholesterol crystallization within hepatocyte lipid droplets (LDs) distinguishes patients with fibrosing NASH from patients with isolated hepatic steatosis and to study pathways leading to cholesterol accumulation in hepatocyte LDs.

Plamen Mihaylov, Richard Mangus, Burcin Ekser, Arianna Cabrales, Lava Timsina, Jonathan Fridell, Marco Lacerda, Marwan Ghabril, Lauren Nephew, Naga Chalasani, Chandrashekhar A. Kubal – 31 March 2019 – Use of donation after circulatory death (DCD) donor livers for transplantation has remained cautious in the United States. The aim of this study was to demonstrate the expansion of a DCD liver transplantation (LT) program with the use of extended criteria donor (ECD) DCD livers. After institutional review board approval, 135 consecutive DCD LTs were retrospectively studied.

Wei‐Yu Kao, Elise Chia‐Hui Tan, Chien‐Wei Su – 30 March 2019

Zachary J. Brown, Tim F. Greten, Bernd Heinrich – 30 March 2019 – Although patients undergo procedures with curative intent for early‐stage hepatocellular carcinoma (HCC), up to 70% of patients may have disease recurrence in the liver at 5 years. Thus far, no therapy has proven to be effective in the adjuvant setting. Here, we discuss the application of immune‐based therapies in the adjuvant setting for HCC, focusing on the underlying rationale for immunotherapies, which patients may benefit from an immune‐based therapy, and what type of immune therapy should be implemented.

Jessica G. Labadie, Manish Jain – 29 March 2019

Gavin Cloherty, Emily Butler, Mary Kuhns – 29 March 2019

Laure Elkrief, José Ferrusquia‐Acosta, Audrey Payancé, Lucile Moga, Luis Tellez, Michael Praktiknjo, Bogdan Procopet, Oana Farcau, Victor De Lédinghen, Rustam Yuldashev, Nicolas Tabchouri, Louise Barbier, Jérôme Dumortier, Benjamin Menahem, Marta Magaz, Virginia Hernández‐Gea, Agustin Albillos, Jonel Trebicka, Laurent Spahr, Andrea De Gottardi, Aurélie Plessier, Dominique Valla, Laura Rubbia‐Brandt, Christian Toso, Christophe Bureau, Juan‐Carlos Garcia‐Pagan, Pierre‐Emmanuel Rautou, for VALDIG, an EASL consortium – 29 March 2019 – In patients with idiopathic noncirrhotic portal hypertension

Gavin Cloherty, Emily Butler, Mary Kuhns – 29 March 2019

Jean‐François Rossignol, Christian Bréchot – 29 March 2019 – Chronic infection by the hepatitis B virus (HBV) has remained a major public health problem. To achieve an HBV cure, we will likely need to combine antivirals with different viral targets as well as immunotherapy. Here, we report data from a pilot proof‐of‐concept clinical trial of nitazoxanide in treating chronic hepatitis B. Conclusion: Nitazoxanide offers novel mechanisms of antiviral activity, and it would be interesting to evaluate the potential of combining nitazoxanide with oral nucleos(t)ide analogues.